SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for NUVB.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2020. Start Trial.
Date Value
March 31, 2026 38.31M
December 31, 2025 40.33M
September 30, 2025 37.36M
June 30, 2025 38.48M
March 31, 2025 35.39M
December 31, 2024 26.14M
September 30, 2024 19.58M
June 30, 2024 16.16M
March 31, 2024 7.357M
December 31, 2023 5.48M
September 30, 2023 7.778M
June 30, 2023 7.541M
March 31, 2023 7.734M
Date Value
December 31, 2022 7.464M
September 30, 2022 8.044M
June 30, 2022 8.948M
March 31, 2022 7.463M
December 31, 2021 7.607M
September 30, 2021 5.669M
June 30, 2021 6.40M
March 31, 2021 4.605M
December 31, 2020 4.432M
September 30, 2020 2.919M
June 30, 2020 1.672M
March 31, 2020 1.925M

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
SIGA Technologies, Inc. 4.673M
Merck & Co., Inc. 2.70B
Pfizer Inc. 2.961B
Alumis, Inc. 18.61M
ANI Pharmaceuticals, Inc. 73.66M